Sheehy Douglas T.
Officer at Aimmune Therapeutics, Inc.; SVP, General Counsel & Sec. at CDXS
- Sold, on record
- $2.9M
- Dollars the filings state
- Form 4 sales
- 14
- Latest Jan 16, 2020
- Form 144 notices
- 0
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- Aimmune Therapeutics, Inc.Officer
- CDXSCODEXIS, INC.SVP, General Counsel & Sec.
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- Aimmune Therapeutics, Inc.86,711 shares
- CDXS3,800 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale Aimmune Therapeutics, Inc.UnusualDec 26, 2017 2017
Sold 1,875 shares at $39.44 ($74k)
Sheehy Douglas T., Officer
Sold 100% of holdings ($74k position)0 shares left0.5x usual sizeFiling
- 2 Form 4 sale Aimmune Therapeutics, Inc.UnusualJan 4, 2018 +9 days
Sold 1,648 shares at $37.33 ($62k)
Sheehy Douglas T., Officer
Sold 100% of holdings ($62k position)0 shares left0.6x usual sizeFiling
- 3 Form 4 sale Aimmune Therapeutics, Inc.UnusualJan 24, 2018 +20 days
Sold 1,875 shares at $38.15 ($72k)
Sheehy Douglas T., Officer
Sold 100% of holdings ($72k position)0 shares left1x usual sizeFiling
- 4 Form 4 sale Aimmune Therapeutics, Inc.UnusualFeb 5, 2018 +12 days
Sold 1,648 shares at $35.87 ($59k)
Sheehy Douglas T., Officer
Sold 100% of holdings ($59k position)0 shares left0.9x usual sizeFiling
- 5 Form 4 sale Aimmune Therapeutics, Inc.Plan not statedMar 5, 2018 +28 days
Sold 3,523 shares at $36.52 ($129k)
Sheehy Douglas T., Officer
Sold 9.8% of holdings ($1.3M position)32,500 shares left1.8x usual sizeFiling
- 6 Form 4 sale Aimmune Therapeutics, Inc.Plan not statedMay 22, 2018 +78 days
Sold 3,296 shares at $33.00 ($109k)
Sheehy Douglas T., Officer
Sold 9.1% of holdings ($1.2M position)33,079 shares left1.7x usual sizeFiling
- 7 Form 4 sale Aimmune Therapeutics, Inc.UnusualDec 26, 2019 +583 days
Sold 10,000 shares at $33.03 ($330k)
Sheehy Douglas T., Officer
Sold 18% of holdings ($1.8M position)45,668 shares left5.3x usual sizeFiling
- 8 Form 4 sale Aimmune Therapeutics, Inc.Plan not statedJan 16, 2020 +21 days
Sold 400 shares at $37.00 ($15k)
Sheehy Douglas T., Officer
Sold 0.9% of holdings ($1.7M position)45,668 shares left0.1x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (14)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jan 16, 2020 | Jan 21, 2020 | Aimmune Therapeutics, Inc. | Officer | Form 4 sale | 400 | $15k | 0.9% | Plan not stated | SEC |
| Dec 26, 2019 | Dec 30, 2019 | Aimmune Therapeutics, Inc. | Officer | Form 4 sale | 10,000 | $330k | 18.0% | Unusual | SEC |
| May 22, 2018 | May 24, 2018 | Aimmune Therapeutics, Inc. | Officer | Form 4 sale | 3,296 | $109k | 9.1% | Plan not stated | SEC |
| Mar 5, 2018 | Mar 6, 2018 | Aimmune Therapeutics, Inc. | Officer | Form 4 sale | 3,523 | $129k | 9.8% | Plan not stated | SEC |
| Feb 5, 2018 | Feb 7, 2018 | Aimmune Therapeutics, Inc. | Officer | Form 4 sale | 1,648 | $59k | 100.0% | Unusual | SEC |
| Jan 24, 2018 | Jan 26, 2018 | Aimmune Therapeutics, Inc. | Officer | Form 4 sale | 1,875 | $72k | 100.0% | Unusual | SEC |
| Jan 4, 2018 | Jan 8, 2018 | Aimmune Therapeutics, Inc. | Officer | Form 4 sale | 1,648 | $62k | 100.0% | Unusual | SEC |
| Dec 26, 2017 | Dec 28, 2017 | Aimmune Therapeutics, Inc. | Officer | Form 4 sale | 1,875 | $74k | 100.0% | Unusual | SEC |
| Dec 4, 2017 | Dec 6, 2017 | Aimmune Therapeutics, Inc. | Officer | Form 4 sale | 1,906 | $74k | 100.0% | Unusual | SEC |
| Nov 30, 2017 | Dec 4, 2017 | Aimmune Therapeutics, Inc. | Officer | Form 4 sale | 3,750 | $139k | 100.0% | Unusual | SEC |
| Nov 9, 2017 | Nov 13, 2017 | Aimmune Therapeutics, Inc. | Officer | Form 4 sale | 1,905 | $63k | 100.0% | Unusual | SEC |
| Oct 23, 2017 | Oct 25, 2017 | Aimmune Therapeutics, Inc. | Officer | Form 4 sale | 47,425 | $1.6M | 100.0% | Unusual | SEC |
| Jul 21, 2017 | Jul 21, 2017 | Aimmune Therapeutics, Inc. | Officer | Form 4 sale | 7,460 | $162k | 100.0% | Unusual | SEC |
| Sep 14, 2012 | Sep 14, 2012 | CDXS | SVP, General Counsel & Sec. | Form 4 sale | 3,800 | $10k | 5.2% | Plan not stated | SEC |